A prospective, randomized clinical trial of cyclosporine reduction in stable patients greater than 12 months after renal transplantation

Abstract

This study suggests that a strategy consisting of a 50% CsA reduction is safe and is not associated with the increased risk of acute rejection observed in CsA withdrawal studies. It also has the potential to improve short-term allograft function and appears to reduce cardiovascular risk factors such as hypertension and hyperlipidemia.